首页 > 市场调查报告书 > 製药

神经疾病

市场调查报告书

商品编码

1633568

感觉异常治疗市场规模、份额和增长分析（按疾病类型、适应症、药物类别、分销渠道、最终用户和地区）- 行业预测，2025-2032 年

Paresthesia Treatment Market Size, Share, Growth Analysis, By Disorder Type (Acute Paresthesia, Chronic Paresthesia), By Indication (Radiculopathy, Neuropathy), By Drug Class, By Distribution Channel, By End User, By Region - Industry Forecast 2025-2032

出版日期: 2025年01月11日 | 出版商:

SkyQuest | 英文 203 Pages | 商品交期: 3-5个工作天内

价格

简介目录

2023 年全球感觉异常治疗市场规模价值 55 亿美元，预计将从 2024 年的 57.1 亿美元增长到 2032 年的 76.9 亿美元，预测期内（2025-2032 年）的复合年增长率为 3.8%。

感觉异常的特征是身体各部位，特别是手脚出现灼热、刺痛或麻木感，越来越被认为是各种医疗问题的重要指标。这种情况的根源在于神经损伤、压迫和血流不畅，通常预示着潜在的问题，例如第 1 型和第 2 型糖尿病、维生素缺乏、神经病变和腕管综合症。随着对这些相关性的认识不断提高，对治疗解决方案的需求也日益增长，针对感觉异常原因的诊断和治疗的潜在市场机会也日益增加。医疗保健提供者和製药公司可以利用这个市场，开发标靶治疗和患者教育资源来有效解决这种复杂的情况，为经历这种痛苦情况的患者提供更好的管理选择。

北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲国家
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 其他亚太地区
拉丁美洲
- 巴西
- 其他拉丁美洲国家
中东和非洲
- 海湾合作委员会国家
- 南非
- 其他中东和非洲地区

竞争资讯

前 5 家公司对比
主要企业市场定位（2024年）
主要市场参与者所采用的策略
近期市场趋势
公司市场占有率分析（2024 年）
主要企业简介
- 公司简介
- 产品系列分析
- 按细分市场分析市场份额
- 收益与前一年同期比较（2022-2024 年）

主要企业简介

Medtronic plc（Ireland）
Boston Scientific Corporation（United States）
Abbott Laboratories（United States）
Nevro Corp.（United States）
Stryker Corporation（United States）
Pfizer Inc.（United States）
GlaxoSmithKline plc（United Kingdom）
Baxter International Inc.（United States）
Glenmark Pharmaceuticals Ltd.（India）
Omron Healthcare, Inc.（United States）
Stimwave LLC（United States）
Cyberonics, Inc.（United States）
EnteroMedics Inc.（United States）
Bio-Medical Research Ltd.（United Kingdom）
Sanofi SA（France）
Bristol-Myers Squibb Company（United States）
Johnson & Johnson（United States）
Novartis International AG（Switzerland）
AstraZeneca plc（United Kingdom）

结论和建议

简介目录

Product Code: SQMIG35A2802

Global Paresthesia Treatment Market size was valued at USD 5.5 billion in 2023 and is poised to grow from USD 5.71 billion in 2024 to USD 7.69 billion by 2032, growing at a CAGR of 3.8% during the forecast period (2025-2032).

Paresthesia, characterized by sensations like burning, tingling, and numbness in various body parts (especially hands and feet), is increasingly recognized as a significant indicator of various medical issues. Rooted in nerve damage, compression, or impaired blood flow, this condition often signals underlying problems, including type 1 and type 2 diabetes, vitamin deficiencies, neurological disorders, and carpal tunnel syndrome. As awareness of these correlations grows, there is a potential market opportunity for diagnostics and treatments targeting the causes of paresthesia, alongside increased demand for therapeutic solutions. Healthcare providers and pharmaceutical companies could capitalize on this market by developing targeted therapies and patient education resources to address this complex condition effectively, enhancing management options for patients experiencing these distressing symptoms.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Paresthesia Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Paresthesia Treatment Market Segmental Analysis

Global Paresthesia Treatment Market is segmented by Disorder Type, Indication, Drug Class, Distribution Channel, End User and region. Based on Disorder Type, the market is segmented into Acute Paresthesia and Chronic Paresthesia. Based on Indication, the market is segmented into Radiculopathy and Neuropathy. Based on Drug Class, the market is segmented into Anticonvulsants, Immunosuppressants, Antidepressants, Opioids and Other. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on End User, the market is segmented into Hospitals, Clinics and Diagnosis Centers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Paresthesia Treatment Market

The global market for paresthesia treatment is significantly driven by the rising prevalence of chronic illnesses, including diabetes, neuropathy, and autoimmune disorders. These medical conditions often lead to paresthesia, which is marked by abnormal sensations like tingling and numbness. As paresthesia frequently indicates underlying health issues, the demand for effective management and treatment options is escalating. Furthermore, with more individuals undergoing anesthesia procedures, healthcare professionals must cater to the growing population of patients experiencing anesthesia-related complications, further amplifying the need for innovative and accessible solutions in the paresthesia treatment market.

Restraints in the Global Paresthesia Treatment Market

Restraints in the Global Paresthesia Treatment market include the potential adverse effects linked to specific therapies. Patients undergoing treatments like nerve stimulation or chemotherapy may encounter reactions such as discomfort or complications, which could hinder their acceptance of these methods. Concerns regarding safety and tolerability significantly impact both patient and physician willingness to adopt these interventions. Furthermore, the variability in individual responses to treatments poses a unique challenge for healthcare professionals, who must thoughtfully consider and customize treatment plans for each patient to ensure optimal outcomes, emphasizing the importance of a mindful and personalized approach in managing paresthesia.

Market Trends of the Global Paresthesia Treatment Market

The Global Paresthesia Treatment market is witnessing a significant upward trend, primarily fueled by the rising prevalence of neurological disorders like multiple sclerosis, diabetic neuropathy, and carpal tunnel syndrome. As the global population ages, the susceptibility to conditions such as strokes and other neurological diseases is increasing, intensifying the demand for effective anesthetic treatments. Furthermore, technological advancements in therapeutic devices, including transcutaneous electrical stimulation (TENS) and ultrasound devices, are enhancing treatment efficacy and patient outcomes. This convergence of demographic shifts and innovation in treatment modalities is expected to propel substantial growth in the paresthesia treatment market throughout the forecast period.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Case Studies
Regulatory Landscape
Patent Analysis

Global Paresthesia Treatment Market Size by Disorder Type & CAGR (2025-2032)

Market Overview
Acute Paresthesia
Chronic Paresthesia

Global Paresthesia Treatment Market Size by Indication & CAGR (2025-2032)

Market Overview
Radiculopathy
Neuropathy

Global Paresthesia Treatment Market Size by Drug Class & CAGR (2025-2032)

Market Overview
Anticonvulsants
Immunosuppressants
Antidepressants
Opioids
Other

Global Paresthesia Treatment Market Size by Distribution Channel & CAGR (2025-2032)

Market Overview
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Global Paresthesia Treatment Market Size by End User & CAGR (2025-2032)

Market Overview
Hospitals
Clinics
Diagnosis Centers

Global Paresthesia Treatment Market Size & CAGR (2025-2032)

North America (Disorder Type, Indication, Drug Class, Distribution Channel, End User)
- US
- Canada
Europe (Disorder Type, Indication, Drug Class, Distribution Channel, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Disorder Type, Indication, Drug Class, Distribution Channel, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Disorder Type, Indication, Drug Class, Distribution Channel, End User)
- Brazil
- Rest of Latin America
Middle East & Africa (Disorder Type, Indication, Drug Class, Distribution Channel, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

Medtronic plc (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boston Scientific Corporation (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Abbott Laboratories (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Nevro Corp. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Stryker Corporation (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Baxter International Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Glenmark Pharmaceuticals Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Omron Healthcare, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Stimwave LLC (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cyberonics, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
EnteroMedics Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bio-Medical Research Ltd. (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb Company (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis International AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca plc (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments